Jennifer Drummond
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jennifer Drummond has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- David A. Wheeler
Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA
3 shared publications - Linghua Wang
Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3 shared publications D M Muzny
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publicationsDavid A. Wheeler
Baylor College of Medicine, Houston, TX
2 shared publicationsH Doddapaneni
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications- Josef T. Prchal
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
2 shared publications
Latest Publications
- 9 November 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (12) , 1426-1434
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes
Madeleine Duvic, David Wheeler and colleagues present an integrated genomic analysis of Sézary syndrome. They identify recurrent alterations in key T cell signaling and differentiation genes and observe overexpression of IL32 and IL2RG in nearly all cases. Sézary syndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized redness, scaling, itching and increased numbers of circulating atypical T lymphocytes. It is rarely curable, with poor prognosis. Here we present a multiplatform genomic analysis of 37 patients with Sézary syndrome that implicates dysregulation of cell cycle checkpoint and T cell signaling. Frequent somatic alterations were identified in TP53, CARD11, CCR4, PLCG1, CDKN2A, ARID1A, RPS6KA1 and ZEB1. Activating CCR4 and CARD11 mutations were detected in nearly one-third of patients. ZEB1, encoding a transcription repressor essential for T cell differentiation, was deleted in over one-half of patients. IL32 and IL2RG were overexpressed in nearly all cases. Our results demonstrate profound disruption of key signaling pathways in Sézary syndrome and suggest potential targets for new therapies.
- 9 November 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (12) , 1426-1434
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes
Madeleine Duvic, David Wheeler and colleagues present an integrated genomic analysis of Sézary syndrome. They identify recurrent alterations in key T cell signaling and differentiation genes and observe overexpression of IL32 and IL2RG in nearly all cases. Sézary syndrome is a rare leukemic form of cutaneous T cell lymphoma characterized by generalized redness, scaling, itching and increased numbers of circulating atypical T lymphocytes. It is rarely curable, with poor prognosis. Here we present a multiplatform genomic analysis of 37 patients with Sézary syndrome that implicates dysregulation of cell cycle checkpoint and T cell signaling. Frequent somatic alterations were identified in TP53, CARD11, CCR4, PLCG1, CDKN2A, ARID1A, RPS6KA1 and ZEB1. Activating CCR4 and CARD11 mutations were detected in nearly one-third of patients. ZEB1, encoding a transcription repressor essential for T cell differentiation, was deleted in over one-half of patients. IL32 and IL2RG were overexpressed in nearly all cases. Our results demonstrate profound disruption of key signaling pathways in Sézary syndrome and suggest potential targets for new therapies.
- Open Access
- 27 January 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (4) , 938-941
The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera
- 27 January 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (4) , 938-941
Open AccessThe relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera
- Open Access
- 13 January 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (4) , 935-938
Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes
To better understand the underlying molecular basis of polycythemia vera (PV), we performed whole-exome sequencing and DNA copy-number analysis of 31 JAK2V617F-positive patients and further investigated the evolution of somatic mutations using longitudinal samples. In addition to JAK2V617F and 9pUPD, we identified frequent recurrent somatic mutation in ASXL1, TET2, DNMT3A, SF3B1 and NF1. Forty two percent of patients had a somatic mutation in at least one epigenetic modifier gene. In 4 of 31 patients, variant allele abundance suggested mutation of JAK2V617F was preceded by other somatic mutations including ASXL1, DNMT3A and SF3B1. Strikingly, in 7 patients, apparent germline variants were detected at COSMIC codons in one or more PV-related genes in which we had also discovered somatic mutations across the cohort, suggesting that some pre-JAK2V617F mutations contribute to substantial T-lymphocyte progeny. This study contributes to novel understanding of the complexity of PV pathogenesis.
- 13 January 2014
- Published by Springer Nature in Leukemia
- Vol. 28 (4) , 935-938
Open AccessWhole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes
To better understand the underlying molecular basis of polycythemia vera (PV), we performed whole-exome sequencing and DNA copy-number analysis of 31 JAK2V617F-positive patients and further investigated the evolution of somatic mutations using longitudinal samples. In addition to JAK2V617F and 9pUPD, we identified frequent recurrent somatic mutation in ASXL1, TET2, DNMT3A, SF3B1 and NF1. Forty two percent of patients had a somatic mutation in at least one epigenetic modifier gene. In 4 of 31 patients, variant allele abundance suggested mutation of JAK2V617F was preceded by other somatic mutations including ASXL1, DNMT3A and SF3B1. Strikingly, in 7 patients, apparent germline variants were detected at COSMIC codons in one or more PV-related genes in which we had also discovered somatic mutations across the cohort, suggesting that some pre-JAK2V617F mutations contribute to substantial T-lymphocyte progeny. This study contributes to novel understanding of the complexity of PV pathogenesis.
- 15 April 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (8_Suppleme) , 1114
Abstract 1114: Polymerase epsilon (POLE) mutations and mutator phenotypes in colorectal and endometrial tumors.
Colorectal rectal and endometrial cancers are divided into microsatellite instable (MSI) and microsatellite stable (MSS) types. MSS tumors have chromosome instability with mutation rates of 1-10/Mb. MSI patients have a better prognosis than MSS patients and are treated less aggressively. These tumors exhibit microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP), an increased mutation rate (10-100/Mb, hypermutated). Here we demonstrate a novel class of tumor in these two diseases exhibiting an ultramutator phenotype with mutation rates exceeding 100/ Mb, MSS and chromosome stable. The ultra-high mutation rates appear to be caused by recurrent mutations in the exonuclease domain of DNA polymerase epsilon (POLE). Matched tumor and normal whole exomes for 512 colorectal and 248 endometrial cancers (TCGA data control center) were evaluated for mutation frequency and MSI status. Among the colorectal tumors, 70/512(14%) were hyper mutated, endometroid tumors had 65/248(26%) hypermutated tumors. Within the hypermutated tumors, we identified tumors with extremely high mutation rates (100 mutations/Mb) termed “ultramutated”. 14 (3%) colorectal and 17 (7%) endometrial were ultramutated. 100% of the colorectal and endometrial ultramutated contain an exonuclease domain mutation in POLE with three recurrently mutated positions: P286R/H/S and V411L and S459F, these mutations are found exclusively in ultramutated samples. The functional relevance of these mutations has been demonstrated by previous mutational analysis of the exonuclease domain in bacteria phage (T4) yeast,and mice. Disruption of residues in the active site leads to high error rates, a mutator phenotype and tumor formation. The defined exonuclease active site aligns closely with the recurrent mutation found in the ultramutated tumors. The ultramuted tumors have a distinct mutation spectrum, occur in context and exhibit strand biases. POLE exonuclease domain mutation tumors have high rates of C to A and T to G mutations with low rates of C to G and T to A. Changes of C to A occur predominately in context of 3’ and 5’ flanking T bases. This mutation spectrum and context of flanking bases suggests replicative strand bias. We found that mutations on the leading strand, exhibited a preference for C to A over G to T (60:40). Suggesting transcription-coupled repair (TCR) plays a role in ultramutation. Our results demonstrate that ultra mutated tumors are driven by recurrent mutations in the exonuclease domain of DNA polymerase epsilon. The distinct mutation spectrum, strand bias and mutation context all suggest TCR is involved in ultramutated tumors. We describe a previously unknown role of POLE in colorectal tumors as well as identification of a previously undescribed hot spot for cancer mutations. Citation Format: Eve Shinbrot, Nils Weinhold, Nikolaus Schultz, Lawrence A. Donehower, Jennifer Drummond, Kyle Chang, Richard Gibbs, Chris Sander, David A. Wheeler. Polymerase epsilon (POLE) mutations and mutator phenotypes in colorectal and endometrial tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1114. doi:10.1158/1538-7445.AM2013-1114
- 15 April 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (8_Suppleme) , 1114
Abstract 1114: Polymerase epsilon (POLE) mutations and mutator phenotypes in colorectal and endometrial tumors.
Colorectal rectal and endometrial cancers are divided into microsatellite instable (MSI) and microsatellite stable (MSS) types. MSS tumors have chromosome instability with mutation rates of 1-10/Mb. MSI patients have a better prognosis than MSS patients and are treated less aggressively. These tumors exhibit microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP), an increased mutation rate (10-100/Mb, hypermutated). Here we demonstrate a novel class of tumor in these two diseases exhibiting an ultramutator phenotype with mutation rates exceeding 100/ Mb, MSS and chromosome stable. The ultra-high mutation rates appear to be caused by recurrent mutations in the exonuclease domain of DNA polymerase epsilon (POLE). Matched tumor and normal whole exomes for 512 colorectal and 248 endometrial cancers (TCGA data control center) were evaluated for mutation frequency and MSI status. Among the colorectal tumors, 70/512(14%) were hyper mutated, endometroid tumors had 65/248(26%) hypermutated tumors. Within the hypermutated tumors, we identified tumors with extremely high mutation rates (100 mutations/Mb) termed “ultramutated”. 14 (3%) colorectal and 17 (7%) endometrial were ultramutated. 100% of the colorectal and endometrial ultramutated contain an exonuclease domain mutation in POLE with three recurrently mutated positions: P286R/H/S and V411L and S459F, these mutations are found exclusively in ultramutated samples. The functional relevance of these mutations has been demonstrated by previous mutational analysis of the exonuclease domain in bacteria phage (T4) yeast,and mice. Disruption of residues in the active site leads to high error rates, a mutator phenotype and tumor formation. The defined exonuclease active site aligns closely with the recurrent mutation found in the ultramutated tumors. The ultramuted tumors have a distinct mutation spectrum, occur in context and exhibit strand biases. POLE exonuclease domain mutation tumors have high rates of C to A and T to G mutations with low rates of C to G and T to A. Changes of C to A occur predominately in context of 3’ and 5’ flanking T bases. This mutation spectrum and context of flanking bases suggests replicative strand bias. We found that mutations on the leading strand, exhibited a preference for C to A over G to T (60:40). Suggesting transcription-coupled repair (TCR) plays a role in ultramutation. Our results demonstrate that ultra mutated tumors are driven by recurrent mutations in the exonuclease domain of DNA polymerase epsilon. The distinct mutation spectrum, strand bias and mutation context all suggest TCR is involved in ultramutated tumors. We describe a previously unknown role of POLE in colorectal tumors as well as identification of a previously undescribed hot spot for cancer mutations. Citation Format: Eve Shinbrot, Nils Weinhold, Nikolaus Schultz, Lawrence A. Donehower, Jennifer Drummond, Kyle Chang, Richard Gibbs, Chris Sander, David A. Wheeler. Polymerase epsilon (POLE) mutations and mutator phenotypes in colorectal and endometrial tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1114. doi:10.1158/1538-7445.AM2013-1114
- 15 April 2012
- Published by American Association for Cancer Research (AACR)
- Vol. 72 (8) , 4922
Abstract 4922: Patterns of tumor evolution in high grade serous ovarian carcinoma
BACKGROUND High grade serous ovarian cancer (HGS-OvCa) is the fifth leading cause of cancer death amongst women in the United States and is characterized by a 25% rate of recurrence within six months after the end of treatment. To gain insight into the mechanisms used by tumor cells to evade the toxic effects of DNA damaging therapy, we genomically characterized sixteen triplets of tumor primary, tumor recurrence and normal samples using whole exome sequencing, DNA copy number arrays, methylation arrays and gene expression arrays. RESULTS Fifteen out of sixteen recurrent samples acquired both somatic mutations as well as DNA copy number alterations, and the number of novel abnormalities acquired was correlated with the time elapsed between primary and recurrence. Interestingly, nine of sixteen recurrence samples harbored only a subset of the mutations identified in the primary tumor. Similarly, these cases appeared to have lost a subset of the copy number alterations with which the primary sample originally presented, suggesting that primary and recurrent tumors were derived from an ancestral clone rather than to have evolved from the dominant clone present at diagnosis. The remaining seven recurrent samples contained all abnormalities found at time of diagnosis and are thus likely to have evolved from the dominant diagnostic clone. The time to recurrence was shorter for ‘diagnostic clone’ patients than for ‘ancestral clone’ patients, with borderline significance (likelihoodratio test p-value 0.08). Analysis of mutation allele fractions suggested a higher degree of tumor heterogeneity in primary tumor samples than in recurrent tumor samples. Recurrence was not associated with a specific mutation or copy number alteration. Tumors from patients whose interval between end of platinum therapy and recurrence was less than six months were not characterized by specific patterns of abnormalities. DISCUSSION Analysis of genomic alterations in primary and recurrent ovarian cancer tumor samples suggests that recurrences can be classified into two dominant groups: recurrences derived from an ancestral clone and recurrences originating from the same dominant clone present at time of diagnosis. Analysis of mutation allele fractions provided further insights into the clonality of primary and recurrent tumor samples. These findings shed light on the mechanism by which tumors overcome the effects of DNA damaging agents and may lead to development of therapies that specifically address the clonal origin properties of recurrent tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4922. doi:1538-7445.AM2012-4922
- 15 April 2012
- Published by American Association for Cancer Research (AACR)
- Vol. 72 (8) , 4922
Abstract 4922: Patterns of tumor evolution in high grade serous ovarian carcinoma
BACKGROUND High grade serous ovarian cancer (HGS-OvCa) is the fifth leading cause of cancer death amongst women in the United States and is characterized by a 25% rate of recurrence within six months after the end of treatment. To gain insight into the mechanisms used by tumor cells to evade the toxic effects of DNA damaging therapy, we genomically characterized sixteen triplets of tumor primary, tumor recurrence and normal samples using whole exome sequencing, DNA copy number arrays, methylation arrays and gene expression arrays. RESULTS Fifteen out of sixteen recurrent samples acquired both somatic mutations as well as DNA copy number alterations, and the number of novel abnormalities acquired was correlated with the time elapsed between primary and recurrence. Interestingly, nine of sixteen recurrence samples harbored only a subset of the mutations identified in the primary tumor. Similarly, these cases appeared to have lost a subset of the copy number alterations with which the primary sample originally presented, suggesting that primary and recurrent tumors were derived from an ancestral clone rather than to have evolved from the dominant clone present at diagnosis. The remaining seven recurrent samples contained all abnormalities found at time of diagnosis and are thus likely to have evolved from the dominant diagnostic clone. The time to recurrence was shorter for ‘diagnostic clone’ patients than for ‘ancestral clone’ patients, with borderline significance (likelihoodratio test p-value 0.08). Analysis of mutation allele fractions suggested a higher degree of tumor heterogeneity in primary tumor samples than in recurrent tumor samples. Recurrence was not associated with a specific mutation or copy number alteration. Tumors from patients whose interval between end of platinum therapy and recurrence was less than six months were not characterized by specific patterns of abnormalities. DISCUSSION Analysis of genomic alterations in primary and recurrent ovarian cancer tumor samples suggests that recurrences can be classified into two dominant groups: recurrences derived from an ancestral clone and recurrences originating from the same dominant clone present at time of diagnosis. Analysis of mutation allele fractions provided further insights into the clonality of primary and recurrent tumor samples. These findings shed light on the mechanism by which tumors overcome the effects of DNA damaging agents and may lead to development of therapies that specifically address the clonal origin properties of recurrent tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4922. doi:1538-7445.AM2012-4922